P53-dependent downregulation of hTERT protein expression and telomerase activity induces senescence in lung cancer cells as a result of pterostilbene treatment

Cell Death and Disease

Volumn 8, Issue 8, 2017, Pages

  Chen, Rong Jane ^a   Wu, Pei Hsuan ^a   Ho, Chi Tang ^b   Way, Tzong Der ^c   Pan, Min Hsiung ^d,e   Chen, Hsiu Min ^f   Ho, Yuan Soon ^f,g   Wang, Ying Jan ^a,g,h,i  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b RUTGERS UNIVERSITY   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e HUANGGANG NORMAL UNIVERSITY   (China)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^h ASIA UNIVERSITY   (Taiwan)

ⁱ CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; PTEROSTILBENE; STILBENE DERIVATIVE; TELOMERASE;

CELL AGING; COMET ASSAY; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELLULAR SENESCENCE; COMET ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LUNG NEOPLASMS; STILBENES; TELOMERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85039749843     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2017.333     Document Type: Article

References (43)

1. Rufini A, Tucci P, Celardo I, Melino G. Senescence and aging: the critical roles of p53. Oncogene 2013; 32: 5129–5143.
2. Bernhart E, Damm S, Heffeter P, Wintersperger A, Asslaber M, Frank S et al. Silencing of protein kinase D2 induces glioma cell senescence via p53-dependent and-independent pathways. Neuro Oncol 2014; 16: 933–945.
3. Luo H, Yang A, Schulte BA, Wargovich MJ, Wang GY. Resveratrol induces premature senescence in lung cancer cells via ROS-mediated DNA damage. PLoS ONE 2013; 8: e60065.
4. Kong Y, Cui H, Ramkumar C, Zhang H. Regulation of senescence in cancer and aging. J Aging Res 2011; 2011: 963172.
5. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev 2010; 24: 2463–2479.
6. Yaswen P, MacKenzie KL, Keith WN, Hentosh P, Rodier F, Zhu J et al. Therapeutic targeting of replicative immortality. Semin Cancer Biol 2015; 35(Suppl): S104–S128.
7. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003; 426: 194–198.
8. Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 2013; 14: 197–210.
9. Lee M, Lee JS. Exploiting tumor cell senescence in anticancer therapy. BMB Rep 2014; 47: 51–59.
10. Zhang Y, Yang JM. The impact of cellular senescence in cancer therapy: is it true or not? Acta Pharmacol Sin 2011; 32: 1199–1207.
11. Burchett KM, Yan Y, Ouellette MM. Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells. PLoS ONE 2014; 9: e85155.
12. Agrawal A, Dang S, Gabrani R. Recent patents on anti-telomerase cancer therapy. Recent Pat Anticancer Drug Discov 2012; 7: 102–117.
13. Kotsakis A, Papadimitraki E, Vetsika EK, Aggouraki D, Dermitzaki EK, Hatzidaki D et al. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. Lung Cancer 2014; 86: 59–66.
14. Fernandez-Garcia I, Ortiz-de-Solorzano C, Montuenga LM. Telomeres and telomerase in lung cancer. J Thorac Oncol 2008; 3: 1085–1088.
15. Wei R, DeVilbiss FT, Liu W. Genetic polymorphism, telomere biology and non-small lung cancer risk. J Genet Genomics 2015; 42: 549–561.
16. McCormack D, McFadden D. Pterostilbene and cancer: current review. J Surg Res 2012; 173: e53–e61.
17. Chen RJ, Ho CT, Wang YJ. Pterostilbene induces autophagy and apoptosis in sensitive and chemoresistant human bladder cancer cells. Mol Nutr Food Res 2010; 54: 1819–1832.
18. Rimando AM, Cuendet M, Desmarchelier C, Mehta RG, Pezzuto JM, Duke SO. Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. J Agric Food Chem 2002; 50: 3453–3457.
19. Ferrer P, Asensi M, Segarra R, Ortega A, Benlloch M, Obrador E et al. Association between pterostilbene and quercetin inhibits metastatic activity of B16 melanoma. Neoplasia 2005; 7: 37–47.
20. Remsberg CM, Yanez JA, Ohgami Y, Vega-Villa KR, Rimando AM, Davies NM. Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity. Phytother Res 2008; 22: 169–179.
21. Tippani R, Prakhya LJ, Porika M, Sirisha K, Abbagani S, Thammidala C. Pterostilbene as a potential novel telomerase inhibitor: molecular docking studies and its in vitro evaluation. Curr Pharm Biotechnol 2014; 14: 1027–1035.
22. Deben C, Deschoolmeester V, Lardon F, Rolfo C, Pauwels P. TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value. Crit Rev Oncol Hematol 2016; 99: 63–73.
23. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 2009; 4: 1798–1806.
24. Leontieva OV, Demidenko ZN, Blagosklonny MV. MEK drives cyclin D1 hyperelevation during geroconversion. Cell Death Differ 2013; 20: 1241–1249.
25. Prieur A, Besnard E, Babled A, Lemaitre JM. p53 and p16(INK4A) independent induction of senescence by chromatin-dependent alteration of S-phase progression. Nat Commun 2011; 2: 473.
26. Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemela M et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov 2013; 3: 182–197.
27. Zannini L, Delia D, Buscemi G. CHK2 kinase in the DNA damage response and beyond. J Mol Cell Biol 2014; 6: 442–457.
28. Xie M, Chen Q, He S, Li B, Hu C. Silencing of the human TERT gene by RNAi inhibits A549 lung adenocarcinoma cell growth in vitro and in vivo. Oncol Rep 2011; 26: 1019–1027.
29. Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev 2013; 39: 444–456.
30. Gerard C, Goldbeter A. The balance between cell cycle arrest and cell proliferation: control by the extracellular matrix and by contact inhibition. Interface Focus 2014; 4: 20130075.
31. Xu D, Wang Q, Gruber A, Bjorkholm M, Chen Z, Zaid A et al. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene 2000; 19: 5123–5133.
32. Marti-Centelles R, Falomir E, Murga J, Carda M, Marco JA. Inhibitory effect of cytotoxic stilbenes related to resveratrol on the expression of the VEGF, hTERTand c-Myc genes. Eur J Med Chem 2015; 103: 488–496.
33. Wu XQ, Huang C, He X, Tian YY, Zhou DX, He Y et al. Feedback regulation of telomerase reverse transcriptase: new insight into the evolving field of telomerase in cancer. Cell Signal 2013; 25: 2462–2468.
34. Li L, Chen DB, Lin C, Cao K, Wan Y, Zhao XY et al. hPNAS-4 inhibits proliferation through S phase arrest and apoptosis: underlying action mechanism in ovarian cancer cells. Apoptosis 2013; 18: 467–479.
35. Collado M, Medema RH, Garcia-Cao I, Dubuisson ML, Barradas M, Glassford J et al. Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J Biol Chem 2000; 275: 21960–21968.
36. An JH, Jang SM, Kim JW, Kim CH, Song PI, Choi KH. The expression of p21 is upregulated by forkhead box A1/2 in p53-null H1299 cells. FEBS Lett 2014; 588: 4065–4070.
37. Chu K, Gao G, Yang X, Ren S, Li Y, Wu H et al. MiR-512-5p induces apoptosis and inhibits glycolysis by targeting p21 in non-small cell lung cancer cells. Int J Oncol 2016; 48: 577–586.
38. Luo J, Meng C, Tang Y, Zhang S, Wan M, Bi Y et al. miR-132/212 cluster inhibits the growth of lung cancer xenografts in nude mice. Int J Clin Exp Med 2014; 7: 4115–4122.
39. Wen FC, Chang TW, Tseng YL, Lee JC, Chang MC. hRAD9 functions as a tumor suppressor by inducing p21-dependent senescence and suppressing epithelial-mesenchymal transition through inhibition of Slug transcription. Carcinogenesis 2014; 35: 1481–1490.
40. Yu SY, Liao CH, Chien MH, Tsai TY, Lin JK, Weng MS. Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer. J Agric Food Chem 2014; 62: 2085–2095.
41. Kovacevic Z, Sivagurunathan S, Mangs H, Chikhani S, Zhang D, Richardson DR. The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis 2011; 32: 732–740.
42. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle 2009; 8: 1888–1895.
43. Wang YJ, Yang MC, Pan MH. Dihydrolipoic acid inhibits tetrachlorohydroquinone-induced tumor promotion through prevention of oxidative damage. Food Chem Toxicol 2008; 46: 3739–3748.